Statin associated muscle symptoms: An update and review

Prog Cardiovasc Dis. 2022 Nov-Dec:75:40-48. doi: 10.1016/j.pcad.2022.11.010. Epub 2022 Nov 16.

Abstract

Statin therapy has been shown to have a significant effect on lowering of low-density lipoprotien cholesterol (LDL-C) levels. This subsequently results in cardiovascular (CV) benefit through reduction in major adverse CV disease (CVD) events and overall mortality. Although there is well proven clinical benefit, statin therapy may be discontinued in some patients, and the most common cause for discontinuation is concern for statin-associated muscle symptoms. However, the data on the true prevalence of these symptoms is mixed and continued studies are showing that the symptoms may be less prevalent than previously believed. With statin-associated muscle symptoms being the most common reason for a patient to not be on statin therapy, it is important for physicians to understand how to evaluate for and manage these symptoms. This manuscript provides an overview of statin associated muscle symptoms so that physicians may be able to better manage patients on statin therapy and continue to use these medications when indicated to best reduce future risk of CVD for patients.

Keywords: Atherosclerotic cardiovascular disease; Cardiac disease prevention; Lipid management; Statin; Statin associated muscles symptoms (SAMS).

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / epidemiology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
  • Muscles

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors